Dyne Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dyne Therapeutics (DYN).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

15Buy

1Hold

1Sell

Consensus RatingBuy# Analysts18Avg. Consensus PT$39Upside to Avg. PT+103.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$45→$36
Sep 9, 2026	JP Morgan	Tessa Romero	Downgrade	Neutral→Underweight	$17→$10
Sep 9, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$35→$30
Sep 9, 2026	Baird	Brian Skorney	PT Cut	Outperform	$30→$26
Jul 31, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$47→$45
Jul 30, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$30→$35
Jul 23, 2026	Cantor Fitzgerald	Eric Schmidt	Initiate	Overweight	—
Jun 26, 2026	TD Cowen	Joseph Thome	Initiate	Buy	—
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$34→$33
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$23→$24
Mar 9, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$50→$47
Mar 3, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$60→$50
Jan 20, 2026	JP Morgan	Tessa Romero	PT Cut	Neutral	$17→$16
Dec 15, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$38→$36
Dec 11, 2025	Stifel	Paul Matteis	PT Raise	Buy	$36→$39
Dec 10, 2025	Oppenheimer	Andreas Argyrides	Upgrade	Perform→Outperform	$11→$40
Dec 9, 2025	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$46→$50
Dec 9, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.

Benzinga Newsdesk

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

PRO
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

People Also Watch

People Also Watch

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PROBaird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

PRORBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

PROCantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

PRO
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating